Locally Advanced Mid/Low Rectal Cancer with Synchronous Liver Metastases

被引:22
|
作者
Vigano, Luca [1 ]
Karoui, Mehdi [2 ]
Ferrero, Alessandro [1 ]
Tayar, Claude [2 ]
Cherqui, Daniel [2 ]
Capussotti, Lorenzo [1 ]
机构
[1] Osped Mauriziano Umberto 1, Dept HPB & Digest Surg, I-10128 Turin, Italy
[2] Univ Paris 12, Hop Henri Mondor, Dept Digest & Hepatobiliary Surg, F-94010 Creteil, France
关键词
MULTIPLE COLORECTAL METASTASES; PREOPERATIVE RADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY; MULTIINSTITUTIONAL ANALYSIS; SIMULTANEOUS RESECTION; 1ST-LINE TREATMENT; PRIMARY TUMOR; SURGERY; CHEMORADIATION; FLUOROURACIL;
D O I
10.1007/s00268-011-1272-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Management of patients with T3/4 and/or N+ mid/low rectal cancer with synchronous liver metastases is not codified. The aim of this study was to analyze outcomes of our approach which consists of neoadjuvant chemotherapy or chemoradiotherapy, according to liver disease extension, followed by simultaneous rectal and liver resection. Between 2000 and 2009, 354 patients underwent hepatectomy for synchronous metastases. Thirty-six consecutive patients who underwent rectal and liver resection for metastatic T3/4 and/or N+ mid/low rectal cancer were analyzed. Liver metastases were multiple in 27 patients, bilobar in 22, and > 5 cm in six. Up-front treatment was chemotherapy in 15 patients, chemoradiotherapy in seven, chemotherapy followed by chemoradiotherapy in six, and surgery in eight (five symptomatic tumors). After chemotherapy alone (median number of cycles = 6), primary tumor response was observed in 11 patients (three complete responses). After chemoradiotherapy, only one patient had liver disease progression. Eighty-nine percent of patients underwent simultaneous rectal and hepatic resection. Mortality and morbidity rates were 2.8% (one pulmonary embolism) and 36%, respectively. After a mean follow-up of 39 months, 5-year overall and disease-free survival were 59.3 and 39.6%, respectively. Twenty-one patients had recurrence, including three pelvic recurrences (8.3%). No pelvic recurrence occurred among patients who correctly completed treatment strategy. All patients who received neoadjuvant chemoradiotherapy were alive and disease-free; 5-year overall and disease-free survival of patients receiving neoadjuvant chemotherapy were 59.3 and 25%, respectively. For patients with metastatic T3/4 and/or N+ mid/low rectal cancer, the present strategy was safe and effective. Good disease control was achieved by neoadjuvant treatments, low morbidity rates were associated with simultaneous resection, and excellent long-term outcomes with low local relapse rate were obtained.
引用
收藏
页码:2788 / 2795
页数:8
相关论文
共 50 条
  • [1] Locally Advanced Mid/Low Rectal Cancer with Synchronous Liver Metastases
    Luca Viganò
    Mehdi Karoui
    Alessandro Ferrero
    Claude Tayar
    Daniel Cherqui
    Lorenzo Capussotti
    [J]. World Journal of Surgery, 2011, 35 : 2788 - 2795
  • [2] Locally advanced mid/low rectal cancer with synchronous resectable liver metastases: systematic review of the available strategies and outcome
    Tutino, R.
    Bonomi, A.
    Zingaretti, C. C.
    Risi, L.
    Ragaini, E. M.
    Vigano, L.
    Paterno, M.
    Pezzoli, I.
    [J]. UPDATES IN SURGERY, 2024, 76 (02) : 345 - 361
  • [3] Locally advanced mid/low rectal cancer with synchronous resectable liver metastases: systematic review of the available strategies and outcome
    R. Tutino
    A. Bonomi
    C. C. Zingaretti
    L. Risi
    E. M. Ragaini
    L. Viganò
    M. Paterno
    I. Pezzoli
    [J]. Updates in Surgery, 2024, 76 : 345 - 361
  • [4] Combined resections for locally advanced rectal cancer with synchronous liver metastases
    Creavin, B.
    Heeney, A.
    Ryan, E.
    Winter, D.
    [J]. BRITISH JOURNAL OF SURGERY, 2017, 104 : 45 - 45
  • [5] The "Liver first approach" for patients with locally advanced rectal cancer with synchronous liver Metastases
    van der Pool, A.
    de Wilt, J.
    Nuytens, J.
    Planting, A.
    Eggermont, A.
    Verhoef, C.
    [J]. DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 654 - 655
  • [6] The liver-first approach for locally advanced rectal cancer and synchronous liver metastases
    Nierop, P. M. H.
    Verseveld, M.
    Galjart, B.
    Rothbarth, J.
    Nuyttens, J. J. M. E.
    van Meerten, E.
    Burger, J. W. A.
    Grunhagen, D. J.
    Verhoef, C.
    [J]. EJSO, 2019, 45 (04): : 591 - 596
  • [7] The "Liver-First Approach" for Patients with Locally Advanced Rectal Cancer and Synchronous Liver Metastases
    Verhoef, Cornelis
    van der Pool, Anne E. M.
    Nuyttens, Joost J.
    Planting, Andre S. T.
    Eggermont, Alexander M. M.
    de Wilt, Johannes H. W.
    [J]. DISEASES OF THE COLON & RECTUM, 2009, 52 (01) : 23 - 30
  • [8] Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases
    Manceau, Gilles
    Brouquet, Antoine
    Bachet, Jean-Baptiste
    Penna, Christophe
    El Hajjam, Mostafa
    Rougier, Philippe
    Nordlinger, Bernard
    Benoist, Stephane
    [J]. SURGERY, 2013, 154 (03) : 528 - 535
  • [9] The Long Term Results of the Liver First Approach in Patients With Locally Advanced Rectal Cancer and Synchronous Liver Metastases
    Ayez, N.
    van der Pool, A.
    Burger, J. W. A.
    Eggermont, A. M. M.
    IJzermans, J. N. M.
    Verhoef, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S409 - S409
  • [10] Treatment of locally advanced rectal cancer and synchronous liver metastases: multicentre comparison of two treatment strategies
    van Rees, Jan M.
    Krul, Myrtle F.
    Kok, Niels F. M.
    Grunhagen, Dirk J.
    Kok, E. N. D.
    Nierop, Pieter M. H.
    Havenga, Klaas
    Rutten, Harm
    Burger, Jacobus W. A.
    de Wilt, Johannes H. W.
    Hagendoorn, Jeroen
    Peters, Femke P.
    Buijsen, Johannes
    Tanis, Pieter J.
    Verhoef, Cornelis
    Kuhlmann, Koert F. D.
    [J]. BRITISH JOURNAL OF SURGERY, 2023, 110 (09) : 1049 - 1052